Scholar Rock price target raised to $72 from $65 at Raymond James
Raymond James increased its price target on Scholar Rock (SRRK) to $72 from $65, maintaining a Strong Buy rating. The FDA approval of ISEMBYLD for SMA could lead to a quick U.S. launch, with potential $2.2B revenue by 2035, according to the analyst.
How this was made
The 30-second read
Why it matters
Analyst upgrade reflects confidence in commercial rollout and long‑term revenue potential.
Market read
The price‑target increase may prompt short‑term buying pressure on SRRK.
What to watch
Potential competition and reimbursement uncertainties may temper upside.
Background
Scholar Rock recently received FDA approval for its SMA therapy ISEMBYLD, indicating a potential revenue runway.
Ticker impact
Raymond James raised Scholar Rock's price target to $72 from $65 and kept a Strong Buy rating.
Potential short-term upside as investors adjust expectations.
Target raise signals confidence in upcoming FDA‑approved product launch, but impact depends on broader market sentiment.
Market effects
Positive signal for biotech sector, especially companies with FDA approvals.
May boost US biotech stocks in the near term.
Limited to investors tracking US-listed biotech firms.
Counterpoint
Target raise could be premature if launch execution faces delays.
Key entities
- companyScholar Rock
Biotech firm with FDA‑approved SMA therapy.
- analystRaymond James
Investment bank that raised the price target.
